Role of linezolid in the treatment of complicated skin and soft tissue infections
- PMID: 16771613
- DOI: 10.1586/14787210.4.3.357
Role of linezolid in the treatment of complicated skin and soft tissue infections
Abstract
Staphylococcus aureus is the most common cause of complicated skin and soft tissue infections (cSSTIs). Antibiotic choices for these infections continue to evolve. History has seen penicillin progress to antistaphylococcal penicillins and cephalosporins, but these drugs are now giving way to drugs that are effective against methicillin-resistant S. aureus (MRSA). While vancomycin has been the gold standard to treat MRSA infections, newer therapeutic options have been developed over the last 5 years. These include quinupristin-dalfopristin, daptomycin, tigecycline and linezolid, which is the focus for this review. Linezolid is efficacious in the treatment of cSSTIs (including diabetic foot infections) caused by Gram-positive organisms (including MRSA), with a well-defined safety profile and straightforward dosing. It is also approved for nosocomial pneumonia, community-acquired pneumonia and uncomplicated skin and skin structure infections. Linezolid has an oral and parenteral formulation, which are equivalent. The oral formulation has the potential to offer economic benefits as compared with other therapies. Currently, there are only a few new antibiotics in development with MRSA activity. The proper use of all antibiotics, including these newer agents, is increasingly important if we are to slow the evolution of microbial resistance.
Similar articles
-
The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid.Curr Med Res Opin. 2010 Mar;26(3):571-88. doi: 10.1185/03007990903512057. Curr Med Res Opin. 2010. PMID: 20055750 Review.
-
Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.Ann Pharmacother. 2006 Jun;40(6):1017-23. doi: 10.1345/aph.1G728. Epub 2006 May 23. Ann Pharmacother. 2006. PMID: 16720705 Clinical Trial.
-
Cost-effectiveness of linezolid versus vancomycin for hospitalized patients with complicated skin and soft-tissue infections in France.Med Mal Infect. 2009 May;39(5):330-40. doi: 10.1016/j.medmal.2009.01.005. Epub 2009 Mar 21. Med Mal Infect. 2009. PMID: 19304423
-
Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis.Curr Med Res Opin. 2010 Feb;26(2):407-21. doi: 10.1185/03007990903454912. Curr Med Res Opin. 2010. PMID: 20001574
-
A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus.J Drugs Dermatol. 2007 Jan;6(1):97-103. J Drugs Dermatol. 2007. PMID: 17373167 Review.
Cited by
-
Exosomes and Macrophages: Bidirectional Mutual Regulation in the Treatment of Diabetic Complications.Cell Mol Bioeng. 2024 Aug 31;17(4):243-261. doi: 10.1007/s12195-024-00816-z. eCollection 2024 Aug. Cell Mol Bioeng. 2024. PMID: 39372550 Review.
-
Formulation and Optimization of Solid Lipid Nanoparticle-based Gel for Dermal Delivery of Linezolid using Taguchi Design.Recent Adv Antiinfect Drug Discov. 2024;19(4):322-347. doi: 10.2174/0127724344280309240103062810. Recent Adv Antiinfect Drug Discov. 2024. PMID: 38243985
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical